Immunovant (IMVT)
(Real Time Quote from BATS)
$28.56 USD
+0.22 (0.78%)
Updated Sep 24, 2024 12:38 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Immunovant, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 283 | 218 | 156 | 108 | 66 |
Income After Depreciation & Amortization | -283 | -218 | -156 | -108 | -66 |
Non-Operating Income | 24 | 7 | -1 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -259 | -211 | -157 | -108 | -66 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -259 | -211 | -157 | -107 | -66 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -259 | -211 | -157 | -107 | -66 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -282 | -218 | -156 | -108 | -66 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -283 | -218 | -156 | -108 | -66 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 138.10 | 123.08 | 109.68 | 87.76 | 43.20 |
Diluted EPS Before Non-Recurring Items | -1.78 | -1.71 | -1.43 | -1.22 | -1.54 |
Diluted Net EPS (GAAP) | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 |
Fiscal Year end for Immunovant, Inc falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 94.28 | 80.88 | 61.56 | 61.80 | 78.48 |
Income After SG&A, R&D, and Dept/Amort Expenses | -94.28 | -80.88 | -61.56 | -61.80 | -78.48 |
Non-Operating Income | 7.21 | 5.79 | 10.03 | 3.59 | 4.53 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -87.07 | -75.09 | -51.53 | -58.21 | -73.95 |
Income Taxes | 0.08 | 0.23 | -0.11 | 0.45 | -0.01 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -87.15 | -75.32 | -51.42 | -58.66 | -73.94 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -87.15 | -75.32 | -51.42 | -58.66 | -73.94 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 146.09 | 145.36 | 144.52 | 131.16 | 130.50 |
Diluted EPS Before Non-Recurring Items | -0.60 | -0.52 | -0.36 | -0.45 | -0.47 |
Diluted Net EPS (GAAP) | -0.60 | -0.50 | -0.36 | -0.45 | -0.57 |